The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
	Previous	-	
CIK (Filer ID Number)	Names	X None	Entity Type
0001620463			X Corporation
Name of Issuer			Limited Partnership
M3 Biotechnology, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Orga	ınization		
DELAWARE			General Partnership
Year of Incorporation/Organization	n		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spec	ifv Year)		
Yet to Be Formed	.,		
ret to be ronned			
2. Principal Place of Business a	and Contact Information		
Name of Issuer			
M3 Biotechnology, Inc.			
Street Address 1		Street Address 2	
4000 MASON ROAD, SUITE 300		BOX 352141	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SEATTLE	WASHINGTON	981952141	2062218112
3. Related Persons			
Last Name	First Name		Middle News
			Middle Name
Kawas	Leen		
Street Address 1	Street Address 2		
4000 Mason Road, Suite 300	Box 352141		710/0 (10 1
City	State/Province/Co	untry	ZIP/PostalCode
Seattle	WASHINGTON		981952141
Relationship: X Executive Office	er X Director Promoter		
Clarification of Response (if Nece	ssary):		
Last Name	First Name		Middle Name
Harding	Joseph		W.
Street Address 1	Street Address 2		
4000 Mason Road, Suite 300	Box 352141		
City	State/Province/Co	untry	ZIP/PostalCode
Seattle	WASHINGTON	•	981952141
Relationship: Executive Office	r X Director Promoter		
Clarification of Response (if Nece	ssary):		
Last Namo	Eirot Nama		Middle Name
Last Name	First Name		Middle Name
Fluke, Jr.	John		M.
Street Address 1	Street Address 2		
4000 Mason Road, Suite 300	Box 352141		710/0 (10 1
City	State/Province/Co	untry	ZIP/PostalCode
Seattle	WASHINGTON		981952141
Relationship: Executive Office	r X Director Promoter		
Clarification of Response (if Nece	ssary):		
Last Name	First Name		Middle Name
Montgomery	Michael		Middle Hallie
Street Address 1	Street Address 2		

4000 Mason Road, Suite 300	Box 352141		
City	State/Province/Country	ZIP/PostalCode	
Seattle	WASHINGTON	981952141	
Relationship: Executive Officer X Direct	or Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Mileson	Glenna		
Street Address 1	Street Address 2		
4000 Mason Road, Suite 300	Box 352141	710/04-10-4-	
City Seattle	State/Province/Country WASHINGTON	ZIP/PostalCode 981952141	
Relationship: X Executive Officer Direct		761732141	
Clarification of Response (if Necessary):	orr tomoter		
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	X Biotechnology	Restaurants	
Commercial Banking	Health Insurance		
Insurance	☐ Heapitale & Dhysisians	Technology	
Investing	Hospitals & Physicians	Computers	
Investment Banking	Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under	Real Estate		
the Investment Company Act of 1940?	Commercial	Airlines & Airports	
		Lodging & Conventions	
∐Yes ∐No	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance	Other Travel	
Business Services	Residential	Other Have	
Energy		Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset	_	
No Revenues	No Aggregate Net	Asset Value	
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,0	000,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50	,000,000	
\$25,000,001 - \$100,000,000	\$50,000,001 - \$10	0,000,000	
Over \$100,000,000	Over \$100,000,00	0	
X Decline to Disclose	Decline to Disclos	е	
Not Applicable	Not Applicable		
-			

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investmen	t Company Act	Section 3(c)	
	Section 3(c)(1)	Section 3(c)(9)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(i)		-,()		
Rule 504 (b)(1)(ii)				
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(Section 3(c)(11)	
Rule 506(c)	Section 3(Section 3(c)(12)	
Securities Act Section 4(a)(5)	Section 3(Section 3(c)(13)	
	Section 3(Section 3(c)(14)	
	Section 3(c)(7)		
7. Type of Filing				
X New Notice Date of First Sale 2018-12-05 First S	Sale Yet to Occu	ır		
Amendment				
8. Duration of Offering				
Does the Issuer intend this offering to last more than one	e year? Ye	s X No		
9. Type(s) of Securities Offered (select all that apply)				
Equity		Pooled	Investment Fund Interests	
X Debt		믐	in-Common Securities	
Option, Warrant or Other Right to Acquire Another Solve Security to be Acquired Upon Exercise of Option, Wa	•	Pight	Property Securities	
to Acquire Security		Other (d	describe)	
10. Business Combination Transaction				
Is this offering being made in connection with a business acquisition or exchange offer?	s combination tra	ansaction, such	as a merger, Yes X No	
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investo	r \$0 USD			
12. Sales Compensation				
Recipient			Number X None	
(Associated) Broker or Dealer X None		,	roker or Dealer CRD Number X None	
Street Address 1 City		Street Address State/Province		ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States†or check individual States	All States	Foreign/nor	n-US	
13. Offering and Sales Amounts				
Total Offering Amount \$1,500,000 USD or Indet	finite			
Total Amount Sold \$1,266,000 USD				
Total Remaining to be Sold \$234,000 USD or Indet	finite			
Clarification of Response (if Necessary):				
14. Investors				
Select if securities in the offering have been or may			qualify as accredited investors, and enter the	,
number of such non-accredited investors who alread Regardless of whether securities in the offering have enter the total number of investors who already have	e been or may b	e sold to persor	ns who do not qualify as accredited investors	5, [10
15. Sales Commissions & Finder's Fees Expenses				

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next of the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
M3 Biotechnology, Inc.	/s/ Leen Kawas	Leen Kawas	Chief Executive Officer	2018-12-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.